FDA approves brodalumab for moderate-to-severe plaque psoriasis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • The U.S. Food and Drug Administration has just approved brodalumab (Siliq) for adults with moderate-to-severe plaque psoriasis.
  • Brodalumab is given via injection.
  • Brodalumab is intended for patients who have failed to respond or have stopped responding to other systemic therapies.
Why ...